Observation on the effect of intraoperative risk management combined with comfort nursing in gynecological laparoscopic surgery

Abstract

To explore the effect of intraoperative risk management combined with comfort nursing in gynecological laparoscopic surgery. A retrospective analysis of 384 cases of laparoscopic surgery subjects admitted from February 2019 to June 2022 in the department of gynecology in our hospital were performed and divided into the control group (n = 192) and observation group (n = 192) according to the difference care that they received. Comfort nursing was taken in the control group, and intraoperative risk management combined with comfort nursing was given in the observation group. The coagulation indexes (activated partial thromboplastin time, prothrombin time, and thrombin time), immune inflammation indexes (monocytes and neutrophils), the incidence of lower limb deep vein thrombosis (DVT) and the satisfaction of nursing care were compared between the 2 groups. After care, activated partial thromboplastin time, prothrombin time, and thrombin time in the observation group were significantly longer than those in the control group, and the counts of monocytes and neutrophils in the observation group were significantly lower than those in the control group (P < .05). The incidence of DVT in the observation group was notablely lower than those in the control group (P = .008). The nursing satisfaction in the observation group was notablely higher than those in the control group (P < .001). Intraoperative risk management combined with comfort nursing intervention can improve the level of coagulation indicators and immune inflammation indicators after gynecological laparoscopic surgery, reduce the incidence of DVT, and improve subject nursing satisfaction.

Table3.docx

“…Recurrence rate was reported in 17 studies (Ma, 2011;Zhang, 2012;Zhou and Liu, 2013;Li, 2014;Chen, 2015;Chen et al, 2015;Dou, 2015;Han, 2016;Xing, 2016;Zhou, 2016;Hu and Y, 2018;Qiu and Wan, 2019;Song et al, 2019;Wang and Bo, 2019;Liu, 2020;Zhao and Xiao, 2020;Tong et al, 2023). Total clinical efficacy rates were reported in 16 trials (Ma, 2011;Ding and Shi, 2012;Zhou and Liu, 2013;Li, 2014;Chen et al, 2015;Dou, 2015;Du, 2015;Zhou, 2016;Chen, 2018;Hu and Y, 2018;Lu et al, 2019;Song et al, 2019;Wang and Bo, 2019;Zhao and Xiao, 2020;Wu and Deng, 2021;Tong et al, 2023). VAS score was reported in 10 trials (Zhang, 2012;Chen, 2015;Chen et al, 2015;Han, 2016;Xing, 2016;Hu and Y, 2018;Song et al, 2019;Zhao and Xiao, 2020;Wu and Deng, 2021;Tong et al, 2023...…”

“…Furthermore, after reviewing the remaining 71 full texts, an additional 49 studies were excluded for the following reasons: participants did not meet the inclusion criteria (n = 24); duplicate publications (n = 1); non-randomization (n = 4); intervention included other medical therapies (n = 17); no relevant outcome (n = 3). Ultimately, 22 eligible RCTs were included (Ma, 2011;Ding and Shi, 2012;Zhang, 2012;Zhou and Liu, 2013;Li, 2014;Chen, 2015;Chen et al, 2015;Dou, 2015;Du, 2015;Han, 2016;Xing, 2016;Zhou, 2016;Chen, 2018;Hu and Y, 2018;Lu et al, 2019;Qiu and Wan, 2019;Song et al, 2019;Wang and Bo, 2019;Liu, 2020;Zhao and Xiao, 2020;Wu and Deng, 2021;Tong et al, 2023).…”

“…Serum level of CA125 was reported in 11 trials (Zhang, 2012;Chen, 2015;Dou, 2015;Du, 2015;Han, 2016;Xing, 2016;Zhou, 2016;Hu and Y, 2018;Lu et al, 2019;Liu, 2020;Zhao and Xiao, 2020). Pregnancy rate was reported in 6 trials (Ding and Shi, 2012;Li, 2014;Qiu and Wan, 2019;Liu, 2020;Zhao and Xiao, 2020;Tong et al, 2023). Fourteen trials reported adverse events (Ding and Shi, 2012;Zhang, 2012;Zhou and Liu, 2013;Chen, 2015;Dou, 2015;Du, 2015;Han, 2016;Xing, 2016;Zhou, 2016;Hu and Y, 2018;Lu et al, 2019;Qiu and Wan, 2019;Wang and Bo, 2019;Liu, 2020).…”

“…Eight of these studies defined recurrence as the reappearance of ovarian endometriotic lesions via ultrasound examination (Zhang, 2012;Han, 2016;Zhou, 2016;Hu and Y, 2018;Wang and Bo, 2019;Liu, 2020;Zhao and Xiao, 2020;Tong et al, 2023). Seven studies defined OEC recurrence as the reappearance of both endometriotic lesions and clinical symptoms (Zhou and Liu, 2013;Li, 2014;Chen, 2015;Chen et al, 2015;Dou, 2015;Xing, 2016;Qiu and Wan, 2019). Meanwhile, two studies characterized OEC recurrence as either the recurrence of endometriotic lesions or clinical symptoms (Ma, 2011;Song et al, 2019).…”

“…A considerable volume of clinical research, encompassing case reports, case series, and randomized controlled trials (RCTs), has demonstrated that CHM could decrease recurrence rates, boost pregnancy rates, and improve the quality of life, bringing new hope for clinical management and the development of novel therapeutic approaches for postoperative OEC (Ma, 2011;Ding and Shi, 2012;Zhang, 2012;Zhou and Liu, 2013;Li, 2014;Chen, 2015;Chen et al, 2015;Dou, 2015;Du, 2015;Han, 2016;Xing, 2016;Zhou, 2016;Chen, 2018;Hu and Y, 2018;Lu et al, 2019;Qiu and Wan, 2019;Song et al, 2019;Wang and Bo, 2019;Liu, 2020;Zhao and Xiao, 2020;Wu and Deng, 2021;Tong et al, 2023). Despite this, debates regarding its efficacy and safety persist.…”